Copyright
©The Author(s) 2024.
World J Stem Cells. Jul 26, 2024; 16(7): 742-759
Published online Jul 26, 2024. doi: 10.4252/wjsc.v16.i7.742
Published online Jul 26, 2024. doi: 10.4252/wjsc.v16.i7.742
Characteristics | Embryonic stem cells | Induced pluripotent stem cells | Adult stem cells | Ref. |
Origin | Inner cell mass of blastocyst | Somatic cells | Postnatal adult tissue | [16] |
Potency | Pluripotent | Pluripotent | Multipotent | [17] |
Self-renewal | Yes | Yes | Limited | [17] |
Teratoma formation | Yes | Yes | No | [18] |
Tumorigenesis | Yes | Yes | No | [18] |
Immune response | Immuno-privileged MHC-I and II present in low level | Not immuno-privileged MHC-I and II present in normal level | MSCs are immuno-privileged and immunosuppressive in nature | [18,19,20,21,22] |
Ethical issue | Serious ethical issue | No ethical issue | No ethical issue | [21] |
- Citation: Sharma P, Maurya DK. Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury. World J Stem Cells 2024; 16(7): 742-759
- URL: https://www.wjgnet.com/1948-0210/full/v16/i7/742.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i7.742